Targeted Intraoperative Radiotherapy

Join Us TOMORROW For Our Upcoming Breast Cancer Q & A Webinar Join Dr. Dennis Holmes from 12:00 pm - 1:30 pm on January 16, 2021 for the second installment of a bimonthly Question and Answer webinar sponsored by the Helen Rey Breast Cancer Research Foundation. Receive live answers to your breast cancer questions about breast cancer screening, diagnosis, surgery, radiation, and cryoablation. You may submit questions in advance: https://docs.google.com/.../1FAIpQLSe13iQXEo4.../...viewform... Also save the date for future webinars: March 20, 2021 May 15, 2021 July 17, 2021 September 18, 2021 November 20, 2021 See more

https://myemail.constantcontact.com/Latest-News-on-Breast-C

https://youtu.be/RYvrKkIS5uE Watch the annual Helen Rey Breast Cancer Research Foundation annual patient appreciation presentation. Due to COVID-19, this year’s event took place on October 3, 2020 as a webinar. The Helen Rey Breast Cancer Research Foundation is a 501(c)(3) non-profit research organization that supports Dr. Holmes's breast cancer research activities. Learn more about recently complete, ongoing, and upcoming breast cancer clinical trials, and other breast cancer advancements.

https://conta.cc/33oA3AP

https://conta.cc/3iuSn1z

I am pleased to share with you the long-term results of the TARGIT-A Trial comparing partial breast single fraction targeted intraoperative radiotherapy (IORT) to 3-6 week post-operative whole breast radiotherapy, demonstrating equivalent long-term outcomes. The paper was published today in the British Journal of Medicine. Recognizing the potential of IORT, I started performing targeted IORT in 2006 as only the second U.S. co-investigator in this 2,298 subject multicenter, in...ternational RCT. These clinical trial results have been a long time coming. It’s been a privilege to participate in this trial and co-author this publication as well as participate in or lead multiple other targeted IORT-related publications/clinical trials, several of which are ongoing. The TARGIT-A trial is largely responsible for establishing IORT as a standard of care option for early stage breast cancer in the U.S. IORT is now covered by Medicare and most health plansthe result of a decade-long advocacy effort. In addition to being efficacious, separate publications have shown targeted IORT to be associated with fewer side effects, improved quality of life, and reduced healthcare cost compared to whole breast radiotherapy. https://www.bmj.com/content/370/bmj.m2836